Source comparison
Tesamorelin for Men: Clinical Studies Comparison
| Study | Population | Dose | Duration | Visceral Fat Reduction | Lean Mass Change | Key Findings ||—|—|—|—|—|—|| Falutz et al. (2010) The Lancet | HIV-associated lipodystrophy, men and women | 2mg daily | 26 weeks | −15.2% (men) | +0.3kg | Preserved insulin s
This comparison does not assign a generated winner or score.
- | Study | Population | Dose | Duration | Visceral Fat Reduction | Lean Mass Change | Key Findings ||—|—|—|—|—|—|| Falutz et al. (2010) The Lancet | HIV-associated lipodystrophy, men and women | 2mg daily | 26 weeks | −15.2% (men) | +0.3kg | Preserved insulin sensitivity; no hyperglycemia || Stanley et al. (2011) JAMA | HIV-positive men with abdominal obesity | 2mg daily | 26 weeks | −2.2kg trunk fat | +0.4kg lean mass | Body composition shift favored muscle retention during fat loss || Rao et al. (2015) Journal of Clinical Endocrinology | Men aged 50–70 with metabolic syndrome | 2mg daily | 52 weeks | −18.7% visceral adipose tissue | No significant change | Improved HOMA-IR and fasting glucose without weight loss || Guaraldi et al. (2013) AIDS | HIV lipodystrophy cohort | 2mg daily | 26 weeks | −12.1% | +0.6kg | Cardiovascular risk markers (triglycerides, LDL) improved independently of total body weight |